So, it is postulated that in GIST, continuation of IM-based therapy for IM-resistant GIST might facilitate disease progression by promoting the malignant behavior of tumors in an FGF2-dependent manner. This evidence concerns the gene FGF2 and gastrointestinal stromal tumor.